The company can apply access strategies such as equitable pricing and/or non-exclusive voluntary licensing to expand patient reach, particularly in countries in scope of the Index where the burden of disease is the highest, such as Sri Lanka (for diabetes) and Afghanistan (for leukaemia).Įxpanded the scope of its Global Public Health organisation to include a focus on Global Surgery, including obstetric fistula. Johnson & Johnson has access strategies in some LMICs for canagliflozin (Invokana®), indicated for type 2 diabetes mellitus, and for ibrutinib (Imbruvica®), indicated for leukaemia.
#Johnson and johnson covid vaccine production registration#
Both products can be filed for registration in countries with a high burden of disease, such as Mozambique, South Africa and Zimbabwe.Įxpand access to patented products in countries with the highest burden of disease.
Johnson & Johnson’s antiretrovirals darunavir/cobicistat (Prezcobix®/Rezolsta®) and darunavir/ cobicistat/emtricitabine/tenofovir alafenamide (Symtuza®) have been filed in 12 and 5 countries in scope of the Index respectively. The company can conduct needs assessments in further countries in sub-Saharan Africa and expand the forum to additional countries where supply chain leadership gaps are seen.įile patented medicines for HIV for registration in more countries.
In response, the company launched the Public Health Supply Chain CEO Forum. These reviews revealed a gap in leadership skills in the supply chain. Johnson & Johnson’s Global Public Health unit conducted supply chain process reviews in sub-Saharan African countries including Kenya, Uganda and Nigeria.
The company can plan beyond registration by including more access components such as equitable pricing plans for each project, including cetrelimab, a monoclonal antibody in development for bladder cancer, and aprocitentan, an investigational treatment for hypertension.Įxpand supply chain process reviews to more countries. Johnson & Johnson has access plans in place for all its late-stage R&D projects in the pipeline. Improve the quality of access plans for R&D projects for non-communicable diseases. It leads in its approach to access strategies for supranationally procured products. The company applies access strategies broadly, with several products having strategies across all country income classifications. The company engages in high-quality capacity building initiatives across all fields (i.e., manufacturing, supply chain and health systems strengthening). Johnson & Johnson performs strongly in this area. It also performs strongly in R&D capacity building and has an access planning framework that covers all projects in the pipeline. The company has a large-sized priority pipeline compared its peers with access plans in place for all late-stage pipeline candidates. Johnson & Johnson is a leading company in this area. It also incentivises its senior executives, the CEO and in-country and regional managers to perform on access-to-medicine goals and discloses the outcomes of its access-to-medicine activities. It has an access-to-medicine strategy integrated into its overall corporate strategy and a robust set of compliance controls to mitigate the risk of non-compliance in countries in scope of the Index. Johnson & Johnson has a strong performance in this area.
0 kommentar(er)
